



**CELLERANT**  
**THERAPEUTICS**

**Cellerant Therapeutics Appoints Ramkumar Mandalam  
as Vice President of Pharmaceutical Operations**

**SAN CARLOS, Calif. – November 1, 2005** – Cellerant Therapeutics, Inc. today announced that Ramkumar Mandalam, Ph.D., has joined Cellerant Therapeutics as Vice President of Pharmaceutical Operations. Dr. Mandalam was formerly Executive Director of Product Development for Geron Corporation.

“Ram is an instrumental addition to our team as he brings with him extensive experience in the production of cell-based products and the regulation and manufacture of cell products and biologics. Ram’s technical and industry knowledge will be particularly valuable as we bring our lead product CLT-001, a highly purified adult blood stem cell infusion, into the clinic, and move forward with the development and manufacturing of the other products in our pipeline,” stated Bruce Cohen, President and CEO of Cellerant.

“Cellerant is a leader in cell-based therapies for complex, life-threatening diseases. The company’s technology platform, based on adult blood-forming stem cells, represents a unique approach to therapy which moves cell therapy from personalized medicine to off-the-shelf product manufacturing,” stated Dr. Mandalam. “I am excited about the prospect of advancing the company’s ambitious programs and setting the standard for the development and manufacture of a wide range of cell-based drugs and services.”

Dr. Mandalam was previously Executive Director of Product Development at Geron Corporation, where he managed the development and manufacturing of cell based

therapies for treatment of degenerative diseases and cancer. Prior to Geron, he was Director of Developmental Research at Aastrom Biosciences, where he was responsible for the research and development programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. Dr. Mandalam is the author or co-author of several publications, patent applications, and abstracts.

### **About Cellerant Therapeutics**

Cellerant Therapeutics is a commercial-stage company developing a portfolio of products and services focused on the regulation of the hematopoietic (blood-forming) system. Our products are based on adult hematopoietic stem and progenitor cells as both therapeutic agents and targets for drug discovery. Visit our website at <http://www.cellerant.com>.

### **For more information on Cellerant, please contact:**

Chuck Dubuque  
Cellerant Therapeutics, Inc.  
(650) 232-2104  
[cdubuque@cellerant.com](mailto:cdubuque@cellerant.com)

Kari Watson or Doug MacDougall  
MacDougall Biomedical Communications  
(508) 647-0209  
[kari@macbiocom.com](mailto:kari@macbiocom.com)  
[doug@macbiocom.com](mailto:doug@macbiocom.com)

###